S
SiyoMicro
Bioactive enzyme and small molecule product development
About SiyoMicro
Shenzhen Siyomicro Bio-Tech Co., Ltd. customizes the design and transformation of microbes to develop enzyme preparations and bioactive small molecule products. The company was co-founded by a team of PhDs from the Institute of Microbiology at the Chinese Academy of Sciences. In collaboration with the institute, SIYO Bio-Tech established a commercial genome and entity database of microorganisms from extreme environments in China.
The firm's core business focuses on developing microbial enzymes and small molecular substances from these unique environmental resources. Its products, such as Superoxide dismutase (SOD) and Ectoine, serve a wide range of industries including gene detection, in-vitro diagnosis, health products, cosmetology, medicine, food, beverage, and animal nutrition. One of the company's key products, SOD, is noted for its stability and resistance to high temperatures and acid-alkali conditions, making it suitable for cosmetic and medical applications. Another product, Natural Vanillin, is produced via a precision fermentation process.
SIYO Bio-Tech operates through subsidiaries like KiyoBio, which was established in September 2019 as a joint venture with Wuxia Jinghai Amino Acid Co., Ltd. KiyoBio runs a large-scale production facility with an annual output of over 3,000 tons of amino acids and holds certifications such as ISO9001, ISO22000, KOSHER, and HALAL. The company's business model appears to be centered on asset creation and licensing, supplying raw materials and ingredients to various sectors.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Shenzhen, China
- Employees
- 6
- Open positions
- 24
- Dealroom signal
- 24.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jul 2026 | $14M | $344M | Aier Eye Hospital Group · Goldport Capital · Zhongguancun Qihang Fund | ↗ |
| SERIES B✓Equity / VC | Feb 2022 | $28M | $110M | CICC · Aier Eye Hospital Group · Sinvo Group | — |
Growth signals
Latest recorded traffic for SiyoMicro is 340 monthly website visits, down 39.3% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
CICC- AGAier Eye Hospital Group
- SGSinvo Group
Series B and later2 investors entered at this stage
Goldport Capital- ZFZhongguancun Qihang Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about SiyoMicro on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SiyoMicro’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







